# DESCRIPTION

- claim benefit of provisional applications

## BACKGROUND OF THE INVENTION

- introduce FGF21
- describe FGF21 functions
- motivate FGF21 agonistic binding protein

## BRIEF SUMMARY OF THE INVENTION

- introduce β-Klotho binding protein
- describe β-Klotho binding protein embodiments
- introduce FGFR1c binding protein
- describe FGFR1c binding protein embodiments
- introduce bispecific β-Klotho and FGFR1c binding protein
- describe bispecific β-Klotho and FGFR1c binding protein embodiments
- introduce linker sequences
- describe β-Klotho binding domain embodiments
- describe FGFR1c binding domain embodiments
- introduce bispecific β-Klotho and FGFR1c binding protein with linker
- describe bispecific β-Klotho and FGFR1c binding protein with linker embodiments
- introduce half-life extending moiety
- describe polynucleotides and expression vectors

## DETAILED DESCRIPTION OF THE INVENTION

### Definitions

- define section headings
- establish meaning of scientific and technical terms
- define "a" and "an"
- explain use of parentheses in sequence motifs
- define "FGF21-like signaling activity"
- define "binding protein"
- establish criteria for specific binding
- define "monomer domain" and "monomer"
- define "monomer domain variant"
- explain concept of "loop"
- define "cysteine-defined loop sequence"
- define "B-factor-defined loop sequence"
- define "multimer"
- define "family" and "family class"
- define "ligand" and "target molecule"
- define polypeptide, peptide, and protein terms
- define amino acid terms
- define conservative amino acid substitution
- define recombinant and non-recombinant terms
- define nucleic acid sequence
- define encoding
- define promoter
- define vector
- define identical and percent identity
- describe method for calculating percent identity
- define substantially identical
- define heterologous to
- define percentage of sequence identity
- define comparison window
- describe algorithm for optimal alignment
- describe BLAST algorithm
- describe statistical analysis of similarity

### I. INTRODUCTION

- introduce FGF21-mediated signaling
- describe binding proteins

### II. GENERAL DISCUSSION OF MONOMER DOMAINS

- introduce monomer domains
- describe cysteine-rich domains
- discuss disulfide bonds
- list characteristics of monomer domains
- provide examples of monomer domains
- describe LDL receptor class A domain
- discuss A-domain structure and sequence
- provide consensus sequences for A domains
- describe naturally-occurring A-domains
- introduce EGF monomer domains
- describe thrombospondin type 1 domains
- provide consensus sequences for TSP1 domains
- introduce trefoil domains
- describe thyroglobulin domains
- provide examples of proteins containing naturally occurring domains
- define monomer domains
- list exemplary monomer domain sequences
- describe disulfide bonds in monomer domains
- outline methods for identifying monomer domains with desired properties
- discuss non-recombinant and altered monomer domains
- describe monomer domain variants, including ancestral, chimeric, randomized, and mutated domains
- provide methods for generating libraries of chimeric monomer domains
- describe recombinant nucleic acids encoding binding proteins with monomer domains
- discuss optional binding of compositions to affinity materials and use of non-naturally occurring amino acids

### III. MONOMERS OF THE PRESENT DISCLOSURE

- define monomer domains
- describe monomer domain size
- describe monomer domain stability
- describe monomer domain folding
- describe monomer domain structure conservation
- describe monomer domain cysteine residues
- describe monomer domain calcium binding
- describe monomer domain zinc binding
- describe monomer domain selection for target binding
- introduce FGFR1c binding proteins
- describe FGFR1c binding sequences
- introduce β-Klotho binding proteins
- describe β-Klotho binding sequences
- describe β-Klotho dimer binding proteins
- describe β-Klotho dimer binding sequences
- introduce bispecific binding proteins

### IV. IMPROVING SERUM HALF-LIFE

- introduce half-life extender-binding monomers
- describe half-life extender-binding multimers
- describe serum half-life extension

### V. MULTIMERS

- define multimers
- describe multimer composition
- specify monomer domain sizes
- describe multimer binding properties
- introduce avidity effect
- describe multimer libraries
- introduce immuno-domain-containing heteromultimers
- specify monomer domain characteristics
- describe multimer qualities
- introduce ion binding
- describe multimer domain selection
- introduce multimer binding to multiple targets
- describe multimer aggregation
- introduce fusion proteins
- describe pharmaceutical applications
- introduce tissue-specific targeting
- describe linker peptides
- outline multimer production methods
- describe multimer purification methods

### VI. LINKERS

- introduce linkers
- describe linker characteristics and optimization

### VII. IDENTIFYING MONOMERS OR MULTIMERS WITH AFFINITY FOR A TARGET MOLECULE

- identify monomer domains with desired property
- provide plurality of different nucleic acids
- translate nucleic acids to monomer domains
- screen monomer domains for binding
- identify monomer domains that bind ligand
- use mutagenesis to produce monomer domains
- align naturally occurring monomer domains
- design recombinant monomer domain
- generate human chimeric domain library
- modify naturally-occurring human monomer domains
- screen for potential immunogenicity
- compare candidate protein sequence to database
- identify crossover sequences
- design protein library of human-like chimeric proteins
- generate human-like chimeric protein molecules
- recombine oligonucleotides to generate chimeric junctions
- generate altered monomer domains
- recombine nucleic acids to generate full-length monomer domains
- screen library for monomer domains that bind to desired ligand

### VIII. SELECTION OF MONOMER DOMAINS THAT BIND FGFR1c OR β-KLOTHO

- introduce preliminary screens for agents capable of binding to FGFR1c or β-Klotho
- describe binding assays, including ELISA, Alphascreen, immunohistochemical binding assays, flow cytometry
- outline cell-based assays, including whole cells or cell fractions containing FGFR1c and/or β-Klotho
- describe FGFR1c or β-Klotho activity assays to identify modulators of FGFR1c or β-Klotho
- outline activity assays to identify modulators of FGF21-mediated activity
- describe validation studies using animal models
- introduce selection of monomer domains that bind FGFR1c or β-Klotho from a library of domains
- describe translating a plurality of nucleic acids and screening polypeptides for binding to a desired ligand
- outline methods for identifying monomer domains that bind to a ligand, including panning, affinity chromatography, ELISA, Alphascreen, or
- describe selection based on binding to a ligand, including selection based on slow dissociation rate and valency of the ligand
- introduce reporting display vectors or systems, including phage display systems
- describe phage display methods, including presentation of polypeptide sequences on the phage surface
- outline other display systems, including ribosome displays, nucleotide-linked displays, polysome displays, and cell surface displays
- describe screening monomer and multimer libraries for a desired property, such as binding to a ligand
- outline methods for generating variation and screening for a desired property, including recursive screening
- describe binding of compositions to a matrix of an affinity material
- introduce "walking" selection method for generating multimers capable of binding large targets
- describe evolving monomers or multimers, including intra-domain recombination and interdomain recombination
- outline methods for introducing variation into monomers or multimers, including shuffling and overlap PCR
- describe generating multimer libraries by introducing variation at the monomer level and recombining monomer variant libraries
- introduce selection of monomer domains
- display multimers on various systems
- screen for target binding activity
- use two-hybrid screening assay
- screen for multiple ligands simultaneously
- identify individual affinity agents and ligands
- determine affinity agent-ligand pair identity
- combine methods with "walking" to generate multimers
- manipulate selected multimers
- produce linkers, multimers, and libraries
- introduce therapeutic and prophylactic treatment methods
- administer binding proteins to treat diseases
- combine binding proteins with other treatments
- use binding proteins to decrease blood glucose levels
- use binding proteins to reduce inflammatory damage
- administer binding proteins in ex vivo methods
- administer binding proteins in in vivo methods
- introduce transepithelial delivery mechanisms
- describe binding protein design
- identify transporters for binding proteins
- discuss phage library approach
- describe in vivo indirect contact administration
- outline ex vivo methods
- discuss polynucleotide construct design
- describe in vivo transformation methods
- outline composition administration
- discuss immune response enhancement
- describe inducible gene expression systems
- introduce multimer uses
- describe sandwich-based assay approach
- discuss affinity selection methods
- outline agonist and antagonist creation
- describe further multimer applications
- introduce monomer domains and multimers
- describe cloning and expression of monomer domains and multimers
- discuss introduction of vectors into host cells
- describe production of monomer domains and multimers by recombinant techniques
- discuss cell culture conditions
- describe alterations of monomer domains and multimers to improve pharmacological properties
- introduce animal models for testing immunogenicity of binding proteins
- describe method of producing non-human animal models
- discuss use of non-human animal models to screen for immunogenicity
- introduce kits comprising components for disclosed methods
- describe kits for binding assays
- discuss use of kits for therapeutic formulations
- introduce integrated systems for manipulating character strings corresponding to monomer domains and multimers
- describe use of BLAST algorithm for sequence similarity analysis
- discuss use of PILEUP algorithm for multiple sequence alignment
- describe use of computer system for in silico sequence recombination
- discuss output elements for controlling nucleic acid synthesis
- describe integrated system for performing assays and other operations

## EXAMPLES

- describe various examples of monomer domains and multimers

### Example 1

- select monomer domains and create multimers
- express and screen multimers for binding to desired ligand
- repeat diversification and selection process until desired avidity is obtained
- describe creation of multimers with improved avidity or affinity

### Example 2

- describe in vivo intra-protein recombination to generate libraries of greater diversity

### Reagents and Experimental Procedures

- describe construction of pCK-cre-lox-Monomer-loxP vector
- describe construction of fUSE5HA-Monomer-lox-lox vector
- describe construction of pCK-gIII plasmid
- describe in vivo recombination procedure
- describe rescue of phage vector
- describe cloning of 2nd library and transformation into E. coli host

### Example 3

- describe construction of EGF-based monomer library

### Example 4

- describe in vitro intra-protein recombination to generate recombined libraries
- describe method to generate libraries with randomized inter-cysteine loops
- describe creation of multiple separate libraries with randomized inter-cysteine loops
- describe recombination of selected clones from separate libraries
- describe generation of libraries with randomized inter-cysteine loops

### Example 5

- describe optimization of multimers by optimizing monomers and/or linkers for binding to a target

### Example 6

- describe structural analysis of A domains

### Structural Classification of A-domain Positions

- describe structural classification of A-domain positions

### Example 7

- describe phage library screening
- coat target huFGFR1c or rhβ-klotho
- block and wash plates or beads
- add phage to plates or beads
- wash and elute phage
- elute and neutralize phage
- describe phage elution and recovery
- outline infection protocol
- detail titering input phage
- describe harvesting phage
- outline round 2 and 3 panning
- describe optimization of anti-FGFR1c monomers
- describe optimization of anti-rhβ-Klotho monomers
- describe optimization of anti-rhf-3-Klotho monomers
- describe construction of walked dimer libraries
- outline panning protocol for walked dimer libraries
- describe analysis of panning output
- detail phage ELISA protocol
- describe PCR products
- perform protein production
- screen thousands of monomer proteins
- perform FGFR1c and β-Klotho protein ELISA
- perform receptor-Fc protein AlphaScreen binding assay
- perform biotin-target protein AlphaScreen binding assay
- perform AlphaScreen ligand independent inhibition assay
- perform AlphaScreen ligand dependent inhibition assay
- perform AlphaScreen ligand dependent inhibition assay for binding proteins
- describe multimerization and recombination of phage display-selected monomers
- detail protein purification and ligation
- describe transformation and plating of electrocompetent E. coli
- multimerize monomers
- generate walking libraries
- express and purify proteins
- characterize purified monomers
- purify proteins via Ni-NTA resin
- elute and dialyze proteins
- further purify proteins by Q-Sepharose anion exchange
- identify FGFR1c binding monomers
- summarize FGFR1c binding monomers
- list linkers
- present FGFR1c monomers
- present βKlotho binding monomers
- present βKlotho binding dimers
- summarize βKlotho monomers from panning of naïve A1 library
- summarize βKlotho monomers from panning of LNR library
- summarize βKlotho monomers from panning of mutagenesis libraries
- summarize βKlotho walked dimers from panning of walked dimer libraries
- introduce example 7
- summarize β-Klotho walked dimers
- describe consensus sequences
- list linkers
- summarize additional seed sequence
- introduce example 8
- describe generating and screening binding proteins
- detail PCR-based method
- summarize FGFR1c/βKlotho binding proteins
- describe preparation and testing of binding proteins
- introduce example 9
- describe activation of luciferase expression
- detail reporter cell lines
- describe assay procedure
- introduce example 10
- describe identification of specific pairs of FGF receptor and klotho protein co-receptor
- introduce example 11
- describe induction of Erk phosphorylation in cultured human adipocytes
- describe adipocyte treatment protocol
- describe ERK Phospho/Total MSD Assay
- summarize binding proteins with agonist activity
- introduce IgG binders and serum half-life extension
- describe monomer domains that bind to blood factors
- describe IgG Family 2 and 3 consensus motifs
- describe monomer domains that bind to red blood cells or serum albumin
- describe method for extending serum half-life of a protein
- describe half-life extender-binding multimers
- describe serum half-life extension results
- introduce human serum albumin fusions
- describe binding protein-human serum albumin fusions
- describe fusion to a monovalent IgG-Fc domain
- describe binding protein-monovalent human IgG-Fc fusions
- describe PEGylation
- describe cynomolgous monkey study design
- describe food intake results
- describe body weight results
- describe body mass index, abdominal circumference, and skin fold thickness results
- describe oral glucose tolerance test and blood glucose and insulin level results

